CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Apr. 02, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	[1],[2]	$ 4,057	$ 2,595
Short-term investments	[1]	10,503	15,255
Trade accounts receivable, less allowance for doubtful accounts: 2017—$588; 2016—$609	[1]	8,892	8,225
Inventories	[1],[3]	7,415	6,783
Current tax assets	[1]	2,791	3,041
Other current assets	[1]	2,218	2,249
Assets held for sale	[1]	3	801
Total current assets	[1]	35,878	38,949
Long-term investments	[1]	7,346	7,116
Property, plant and equipment, less accumulated depreciation: 2017—$15,050; 2016—$14,807	[1]	13,238	13,318
Identifiable intangible assets, less accumulated amortization	[1],[4]	52,427	52,648
Goodwill	[1]	54,656	54,449
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,909	1,812
Other noncurrent assets	[1]	3,329	3,323
Total assets	[1]	168,784	171,615
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2017—$3,292; 2016—$4,225	[1],[5]	7,680	10,688
Trade accounts payable	[1]	3,393	4,536
Dividends payable	[1]	0	1,944
Income taxes payable	[1]	790	437
Accrued compensation and related items	[1]	1,858	2,487
Other current liabilities	[1]	11,143	11,023
Total current liabilities	[1]	24,864	31,115
Long-term debt	[1],[6]	36,330	31,398
Pension benefit obligations, net	[1]	5,300	6,406
Postretirement benefit obligations, net	[1]	1,742	1,766
Noncurrent deferred tax liabilities	[1]	30,857	30,753
Other taxes payable	[1]	4,027	4,000
Other noncurrent liabilities	[1]	6,918	6,337
Total liabilities	[1]	110,038	111,776
Commitments and Contingencies	[1]
Preferred stock	[1]	23	24
Common stock	[1]	463	461
Additional paid-in capital	[1]	83,111	82,685
Treasury stock	[1]	(89,414)	(84,364)
Retained earnings	[1]	74,847	71,774
Accumulated other comprehensive loss	[1]	(10,594)	(11,036)
Total Pfizer Inc. shareholders’ equity	[1]	58,435	59,544
Equity attributable to noncontrolling interests	[1]	311	296
Total equity	[1]	58,746	59,840
Total liabilities and equity	[1]	$ 168,784	$ 171,615

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] The change from December 31, 2016 reflects the build of inventory primarily for new product launches and to meet targeted levels for certain products, partially offset by inventory reductions in the normal course of business, including those related to demand.

[4] The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization, partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A).

[5] The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of April 2, 2017 or December 31, 2016. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities carried at cost are based on Level 3 inputs.

[6] The fair value of our long-term debt (not including the current portion of long-term debt) was $40.4 billion as of April 2, 2017 and $34.9 billion as of December 31, 2016. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of $4.3 billion as of April 2, 2017, which are used as hedging instruments.